Phase I study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

Do-Youn Oh,Se-Hoon Lee,Sae-Won Han,Mi-Jung Kim,Tae Min Kim,Tae-You Kim,Dae Seog Heo,Miyuki Yuasa,Yasuo Yanagihara,Yung-Jue Bang

Phase I study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

2015

Do-Youn Oh
Se-Hoon Lee
Sae-Won Han
Mi-Jung Kim
Tae Min Kim
Tae-You Kim
Dae Seog Heo
Miyuki Yuasa
Yasuo Yanagihara
Yung-Jue Bang

Purpose OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors.

Keywords:

Pathology
Alternative medicine
Cancer research
Medicine
Pharmacokinetics
Bioinformatics
Colorectal cancer
Internal medicine
Cancer
Toxicity
Vomiting
Adverse effect
Gastroenterology
Nausea
Diarrhea

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations